{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:38:22Z","timestamp":1790858302568,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1038\/bjc.2012.21","type":"journal-article","created":{"date-parts":[[2012,2,14]],"date-time":"2012-02-14T16:37:12Z","timestamp":1329237432000},"page":"839-845","source":"Crossref","is-referenced-by-count":50,"title":["A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer"],"prefix":"10.1038","volume":"106","author":[{"given":"A A","family":"Chiappori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M T","family":"Schreeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M M","family":"Moezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J J","family":"Stephenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Blakely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Salgia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q S","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H J","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D S","family":"Subramaniam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Schnyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M S","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,2,14]]},"reference":[{"key":"BFbjc201221_CR1","first-page":"1036","volume":"145","author":"JM Ben-Ezra","year":"1994","unstructured":"Ben-Ezra JM, Kornstein MJ, Grimes MM, Krystal G (1994) Small cell carcinomas of the lung express the Bcl-2 protein. Am J Pathol 145: 1036\u20131040","journal-title":"Am J Pathol"},{"key":"BFbjc201221_CR2","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nature08822","volume":"463","author":"R Beroukhim","year":"2010","unstructured":"Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao MS, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M (2010) The landscape of somatic copy-number alteration across human cancers. Nature 463: 899\u2013905","journal-title":"Nature"},{"key":"BFbjc201221_CR3","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1593\/neo.101524","volume":"13","author":"EJ Dean","year":"2011","unstructured":"Dean EJ, Cummings J, Roulston A, Berger M, Ranson M, Blackhall F, Dive C (2011) Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer. Neoplasia 13: 339\u2013347","journal-title":"Neoplasia"},{"key":"BFbjc201221_CR4","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1200\/JCO.2010.31.6208","volume":"29","author":"L Gandhi","year":"2011","unstructured":"Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, Hann CL, McKeegan EM, Litvinovich E, Hemken PM, Dive C, Enschede SH, Nolan C, Chiu YL, Busman T, Xiong H, Krivoshik AP, Humerickhouse R, Shapiro GI, Rudin CM (2011) Phase 1 study of navitoclax (ABT-263), a novel BCL-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 29: 909\u2013916","journal-title":"J Clin Oncol"},{"key":"BFbjc201221_CR5","doi-asserted-by":"publisher","first-page":"4539","DOI":"10.1200\/JCO.2005.04.4859","volume":"24","author":"R Govindan","year":"2006","unstructured":"Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, Spitznagel EL, Piccirillo J (2006) Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24: 4539\u20134544","journal-title":"J Clin Oncol"},{"key":"BFbjc201221_CR6","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1152\/jn.00598.2007","volume":"99","author":"JA Hickman","year":"2008","unstructured":"Hickman JA, Hardwick JM, Kaczmarek LK, Jonas EA (2008) Bcl-XL inhibitor ABT-737 reveals a dual role for BCL-XL in synaptic transmission. J Neurophysiol 99: 1515\u20131522","journal-title":"J Neurophysiol"},{"key":"BFbjc201221_CR7","doi-asserted-by":"publisher","first-page":"4038","DOI":"10.1158\/1078-0432.CCR-10-0822","volume":"16","author":"JJ Hwang","year":"2010","unstructured":"Hwang JJ, Kuruvilla J, Mendelson D, Pishvaian MJ, Deeken JF, Siu LL, Berger MS, Viallet J, Marshall JL (2010) Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin Cancer Res 16: 4038\u20134045","journal-title":"Clin Cancer Res"},{"key":"BFbjc201221_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/path.1711770206","volume":"177","author":"SX Jiang","year":"1995","unstructured":"Jiang SX, Sato Y, Kuwao S, Kameya T (1995) Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J Pathol 177: 135\u2013138","journal-title":"J Pathol"},{"key":"BFbjc201221_CR9","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1200\/JCO.2008.20.1061","volume":"27","author":"PN Lara Jr","year":"2009","unstructured":"Lara Jr PN, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR, Chansky K, Gandara DR (2009) Phase III trial of irinotecan\/cisplatin compared with etoposide\/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 27: 2530\u20132535","journal-title":"J Clin Oncol"},{"key":"BFbjc201221_CR10","doi-asserted-by":"publisher","first-page":"19512","DOI":"10.1073\/pnas.0709443104","volume":"104","author":"M Nguyen","year":"2007","unstructured":"Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR, Goulet D, Viallet J, B\u00e9lec L, Billot X, Acoca S, Purisima E, Wiegmans A, Cluse L, Johnstone RW, Beauparlant P, Shore GC (2007) Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1 mediated resistance to apoptosis. Proc Natl Acad Sci 104: 19512\u201319517","journal-title":"Proc Natl Acad Sci"},{"key":"BFbjc201221_CR11","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1182\/blood-2008-02-137943","volume":"113","author":"SM O\u2019Brien","year":"2009","unstructured":"O\u2019Brien SM, Claxton DF, Crump MS, Faderl S, Kipps T, Keating MJ, Viallet J, Cheson BD (2009) Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 113: 299\u2013305","journal-title":"Blood"},{"key":"BFbjc201221_CR12","doi-asserted-by":"crossref","unstructured":"Raza A, Galili N, Borthakur G, Carter TH, Claxton DF, Erba HP, DeAngelo DJ, Berger MS, Schimmer A (2009) A safety and schedule seeking trial of Bcl-2 inhibitor obatoclax in previously untreated older patients with acute myeloid leukemia (AML). J Clin Oncol 27 (15s): Abstract 3579","DOI":"10.1200\/jco.2009.27.15_suppl.3579"},{"key":"BFbjc201221_CR13","doi-asserted-by":"publisher","first-page":"8295","DOI":"10.1158\/1078-0432.CCR-08-0999","volume":"14","author":"AD Schimmer","year":"2008","unstructured":"Schimmer AD, O\u2019Brien S, Kantarjian H, Brandwein J, Cheson BD, Minden MD, Yee K, Ravandi F, Giles F, Schuh A, Gupta V, Andreeff M, Koller C, Chang H, Kamel-Reid S, Berger M, Viallet J, Borthakur G (2008) A phase I study of the pan Bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res 14: 8295\u20138301","journal-title":"Clin Cancer Res"},{"key":"BFbjc201221_CR14","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1158\/1078-0432.CCR-07-4622","volume":"14","author":"AR Shoemaker","year":"2008","unstructured":"Shoemaker AR, Mitten MJ, Adickes J, Ackler S, Refici M, Ferguson D, Oleksijew A, O\u2019Connor JM, Wang B, Frost DJ, Bauch J, Marsh K, Tahir SK, Yang X, Tse C, Fesik SW (2008) Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res 14: 3268\u20133277","journal-title":"Clin Cancer Res"},{"key":"BFbjc201221_CR15","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1056\/NEJMoa071780","volume":"357","author":"B Slotman","year":"2007","unstructured":"Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, Postmus P, Collette L, Senan S, EORTC Radiation Oncology Group and Lung Cancer Group (2007) Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 357: 664\u2013672","journal-title":"N Engl J Med"},{"key":"BFbjc201221_CR16","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1158\/0008-5472.CAN-09-3535","volume":"70","author":"RL Smoot","year":"2010","unstructured":"Smoot RL, Blechacz BR, Werneburg NW, Bronk SF, Sinicrope FA, Sirica AE, Gores GJ (2010) A Bax-mediated mechanism for obatoclax-induced apoptosis of cholangiocarcinoma cells. Cancer Res 70: 1960\u20131969","journal-title":"Cancer Res"},{"key":"BFbjc201221_CR17","doi-asserted-by":"publisher","first-page":"4787","DOI":"10.1200\/JCO.2009.23.1548","volume":"27","author":"MA Socinski","year":"2009","unstructured":"Socinski MA, Smit EF, Lorigan P, Konduri K, Reck M, Szczesna A, Blakely J, Serwatowski P, Karaseva NA, Ciuleanu T, Jassem J, Dediu M, Hong S, Visseren-Grul C, Hanauske AR, Obasaju CK, Guba SC, Thatcher N (2009) Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-na\u00efve patients with extensive-stage small cell lung cancer. J Clin Oncol 27: 4787\u20134792","journal-title":"J Clin Oncol"},{"key":"BFbjc201221_CR18","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1056\/NEJMra035536","volume":"350","author":"A Spira","year":"2004","unstructured":"Spira A, Ettinger D (2004) Multidisciplinary management of lung cancer. N Engl J Med 350: 379\u2013392","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"BFbjc201221_CR19","doi-asserted-by":"publisher","first-page":"ii235","DOI":"10.1093\/annonc\/mdi700","volume":"16","author":"N Thatcher","year":"2005","unstructured":"Thatcher N, Faivre-Finn C, Lorigan P (2005) Management of small-cell lung cancer. Ann Oncol 16 (Suppl 2): ii235\u2013ii239","journal-title":"Ann Oncol"},{"key":"BFbjc201221_CR20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"BFbjc201221_CR21","doi-asserted-by":"publisher","first-page":"138","DOI":"10.2174\/156652408783769580","volume":"8","author":"MR Warr","year":"2008","unstructured":"Warr MR, Shore GC (2008) Unique biology of Mcl-1: therapeutic opportunities in cancer. Curr Mol Med 8: 138\u2013147","journal-title":"Curr Mol Med"},{"key":"BFbjc201221_CR22","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1038\/sj.cdd.4402081","volume":"14","author":"H Zhang","year":"2007","unstructured":"Zhang H, Nimmer PM, Tahir SK, Chen J, Fryer RM, Hahn KR, Iciek LA, Morgan SJ, Nasarre MC, Nelson R, Preusser LC, Reinhart GA, Smith ML, Rosenberg SH, Elmore SW, Tse C (2007) Bcl-2 family proteins are essential for platelet survival. Cell Death Differ 14: 943\u2013951","journal-title":"Cell Death Differ"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc201221.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc201221","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc201221.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T09:07:57Z","timestamp":1684400877000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc201221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["BFbjc201221"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2012.21","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}